ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

ClinicalTrials.gov ID: NCT00534313

Public ClinicalTrials.gov record NCT00534313. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIB, Multi-Dose, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis

Study identification

NCT ID
NCT00534313
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
191 participants

Conditions and interventions

Interventions

  • Abatacept Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2007
Primary completion
Nov 30, 2008
Completion
Apr 30, 2011
Last update posted
Jul 31, 2012

2007 – 2011

United States locations

U.S. sites
19
U.S. states
13
U.S. cities
19
Facility City State ZIP Site status
Rheumatology Associates Of North Alabama Huntsville Alabama 35801
Desert Medical Advances Palm Desert California 92260
Stanford University School Of Medicine Palo Alto California 94304
Boling Clinical Trials Upland California 91786
Joao Nascimento Bridgeport Connecticut 06606
New England Research Associates, Llc Trumbull Connecticut 06611
Sarasota Arthritis Research Center Sarasota Florida 34239
Clinical Pharmacology Study Group Worcester Massachusetts 01610
Justus Fiechtner, Md, Mph Lansing Michigan 48910
St. Paul Rheumatology P.A. Eagan Minnesota 55121
Midwest Arthritis Center Kalamazoo Minnesota 49048
Arthritis Clinic & Carolina Bone & Joint, Pa Charlotte North Carolina 28210
Deaconess Hospital Cincinnati Ohio 45219
Health Research Of Oklahoma Oklahoma City Oklahoma 73103
Altoona Center For Clinical Research Duncansville Pennsylvania 16635
Rheumatic Disease Associates, Ltd. Willow Grove Pennsylvania 19090
Chase, Walter F. Austin Texas 78705
Seattle Rheumatology Associates Seattle Washington 98104
Arthritis Northwest Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00534313, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 31, 2012 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00534313 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →